Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2A6 | P11509 | 1/20 | 0.36 |
| ▸ | ERN1 | O75460 | 5/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | THRB | P10828 | 1/20 | 0.31 |
| ▸ | BLM | P54132 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | TRIM24 | O15164 | 1/20 | 0.30 |
| ▸ | TRIM33 | Q9UPN9 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1493596 | 0.75 | PTPN2 (0.44) | CYP2A6MEN1LMNAKMT2A | |
| SCHEMBL2083549 | 0.73 | ALDH1A1 (0.39) | CYP2A6ERN1LMNAKMT2ATRIM24 | |
| SCHEMBL15651775 | 0.73 | BCAT2 (0.47) | CYP2A6ERN1MEN1KMT2A | |
| SCHEMBL5187882 | 0.69 | KMT2A (0.51) | MEN1LMNAKMT2A | |
| SCHEMBL4113090 | 0.68 | MEN1 (0.31) | MEN1KMT2A | |
| SCHEMBL9444120 | 0.67 | CES2 (0.43) | ERN1MEN1KMT2A | |
| SCHEMBL21580184 | 0.67 | — | — | |
| SCHEMBL1474805 | 0.67 | — | — | |
| SCHEMBL1419542 | 0.66 | CYP2A6 (0.45) | CYP2A6ERN1MEN1LMNATHRB | |
| SCHEMBL2652907 | 0.66 | ALDH1A1 (0.47) | ERN1MEN1LMNAKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090054667-A1 | Transition metal catalyzed cross-coupling of 1-halo-1-haloalkene compounds | REPLIDYNE, INC. (US) | 2009-02-26 | — | — | US | disclosed |
| US-20080194842-A1 | Transition Metal Catalyzed Cross-Coupling Of 1-Halo-1-Haloalkene Compounds | REPLIDYNE, INC. (US) | 2008-08-14 | — | — | US | disclosed |
| WO-2007021693-A2 | TRANSITION METAL CATALYZED CROSS-COUPLING OF 1-HALO-1-HALOALKENE COMPOUNDS | REPLIDYNE, INC. (US) | 2007-02-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090054667-A1 | Transition metal catalyzed cross-coupling of 1-halo-1-haloalkene compounds | TDO2, TALDO1, NAT1 | CYP2A6 201/4885ERN1 1814/4885MEN1 2653/4885 |
| US-20080194842-A1 | Transition Metal Catalyzed Cross-Coupling Of 1-Halo-1-Haloalkene Compounds | TDO2, TALDO1, NAT1 | CYP2A6 201/4885ERN1 1814/4885MEN1 2653/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.